The company's announcement notably does not use the term "artificial pancreas," although the technology is a considerably more significant advance from the 530G threshold suspend of 2013. When the term was attached to that product, the description was met with howls of protest from the type 1 diabetes community.

A study published in the journal Cancer has evaluated that a 2012 recommendation for prostate cancer screening did not change physician behavior.

Mohs surgery is generally the gold standard for rare and more aggressive tumors because of the way the surgeon can ensure the roots of the tumor are gone and because the technique keeps the hole small, said Ally-Khan B. Somani, MD, PhD, at the 25th European Academy of Dermatology and Venereology Congress.

Reimbursement issues surrounding Mohs surgery are getting worse, which provides a challenge for surgeons who would perform the procedure, explained Aleksandar L. Krunic, MD, PhD, during the 25th European Academy of Dermatology and Venereology Congress.

Horizon Blue Cross Blue Shield's annual Patient-Centered Summit covered efforts by the state to expand naloxone access, provide peer support for those rescued from an opioid overdose, and the insurer's prevention practices.

A new study presented at the annual meeting of the American Society for Radiation Oncology has found a significant survival advantage of combining chemotherapy and radiotherapy following surgery in patients with medulloblastoma.

CMS reached its goals for value-based payments in part because of providers’ enthusiasm for new programs, said Kate Goodrich, MD, director of the Quality Measurement and Value-Based Incentives Group in CMS.

Barring major advances in prevention, diagnosis, and treatment of chronic obstructive pulmonary disease (COPD), hospitalizations for the disease will increase by more than 150% over the next 15 years in developed countries

Mix-ups in patient identification are a fairly frequent occurrence that can cause real harm to patients. These events are highly preventable with strategies.

What we're reading, September 28, 2016: a new company will help people fight their medical bills; prescription drug monitoring programs may not be helping the opioid crisis; and why banning pay-for-delay deals may not help to lower costs.

CMS' star ratings for hospitals have been controversial because they penalize hospitals that disproportionately care for the poor and the sick, and efforts by CMS to adjust the methodology haven't really addressed the concerns, explained Ashish K. Jha, MD, MPH, the K.T. Li Professor of Health Policy at the Harvard T.H. Chan School of Public Health and the director of the Harvard Global Health Institute.

According to a new proposal by the Center for American Progress, Medicare and private health insurance companies should have the power to negotiate drug prices with manufacturers, empowered by comparative effectiveness research data.

The effort to reach young adults will allow them to shop for coverage entirely on mobile digital technology. But an economist interviewed earlier this month says it might not be enough.

Both private and public healthcare plans have traditionally used patient cost sharing to keep costs down. However, implementing value-based insurance design may be able to promote efficiency while increasing the use of high-quality care.